GSK PLC (CHIX:GSKl) Stock News, Headlines & Updates
GSK PLC Stock News from GuruFocus
- 1
- 2
Jul 07, 2025
GSK Faces Risks with RSV Vaccine (GSK)
GuruFocus News • 11:58am
Jun 27, 2025
GSK Under Investigation for Discontinuing Flovent HFA Inhaler
GuruFocus News • 9:57am
Jun 24, 2025
FDA Approves GSK's Benlysta Autoinjector for Lupus Treatment
GuruFocus News • 9:56am
FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis
Business Wire • 9:00am
FDA Approves GSK's New Benlysta Autoinjector for Pediatric Lupus Nephritis | GSK Stock News
GuruFocus News • 8:32am
FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis | GSK Stock News
GuruFocus News • 8:25am
Jun 23, 2025
GSK Seeks EMA Approval for Linerixibat in Treating PBC | GSK Stock News
GuruFocus News • 12:31pm
Jun 20, 2025
GSK Experiences Increased Put Activity Amid Anticipated Earnings | GSK Stock News
GuruFocus News • 11:15am
GSK Seeks Approval in Japan to Expand RSV Vaccine Use to Younger Adults | GSK Stock News
GuruFocus News • 5:48am
Jun 16, 2025
GSK (GSK) Sees Significant Bearish Activity in Options Market | GSK Stock News
GuruFocus News • 9:30am
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
Business Wire • 9:00am
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US | GSK Stock News
GuruFocus News • 8:46am
Jun 13, 2025
GSK Applies for Broader Use of RSV Vaccine in Europe
GuruFocus News • 10:58am
GSK Seeks EMA Approval to Broaden Use of RSV Vaccine | GSK Stock News
GuruFocus News • 5:47am
Jun 12, 2025
GSK Licenses Shigella Vaccine Candidate to Bharat Biotech | GSK Stock News
GuruFocus News • 5:30am
Jun 03, 2025
GSK PLC (GSK) Shares Down 3.25% on Jun 3
GuruFocus News • 12:08pm
GSK Downgraded to Hold Despite Strong Year-to-Date Performance | GSK Stock News
GuruFocus News • 3:45am
Jun 02, 2025
FDA Reviews GSK's Linerixibat for Rare Liver Condition | GSK Stock News
GuruFocus News • 5:49am
GSK Acquires Trelegy Ellipta Royalty Rights for $225M | GSK Stock News
GuruFocus News • 5:16am
May 29, 2025
GSK to Unveil Significant Oncology Data at Key Global Conferences | GSK Stock News
GuruFocus News • 8:46am
May 28, 2025
GSK Involved in SCYNEXIS's Phase 3 Study Milestone Dispute | GSK Stock News
GuruFocus News • 7:47am
GSK (GSK) Advances Oral Antibiotic for Complicated UTIs with Phase 3 Trial Success | GSK Stock News
GuruFocus News • 6:48am
GSK Plans to Advance New Drug Filing with Promising Trial Data | GSK Stock News
GuruFocus News • 6:33am
May 23, 2025
GSK (GSK) Faces Minor Dip Amid Positive Developments
GuruFocus News • 3:58pm
GSK's Blenrep Gains EU Panel Support for Multiple Myeloma Treatment
GuruFocus News • 7:56am
GSK (GSK) Awaits European Commission Decision on Blenrep Approval | GSK Stock News
GuruFocus News • 7:00am
May 22, 2025
FDA Approves GSK's Nucala for COPD Treatment | GSK stock news
GuruFocus News • 4:05pm
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
Business Wire • 4:00pm
FDA Approves GSK's Nucala as Add-On Treatment for COPD Patients | GSK Stock News
GuruFocus News • 3:45pm
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD) | GSK Stock News
GuruFocus News • 3:32pm
GSK Gains FDA Approval for Expanded Use of COPD Therapy
GuruFocus News • 2:57pm
FDA Approval Boosts GSK's Nucala for COPD Treatment | GSK Stock News
GuruFocus News • 1:15pm
May 19, 2025
GSK Secures Approval in Japan for Blenrep Combinations in Myeloma Treatment | GSK Stock News
GuruFocus News • 5:45am
May 14, 2025
GSK to Acquire Efimosfermin Alfa to Boost Liver Disease Treatments | GSK Stock News
GuruFocus News • 6:16am
GSK (GSK) Discontinues Belrestotug Program Amid Study Setbacks | GSK Stock News
GuruFocus News • 6:00am
GSK (GSK) and iTeos Halt Belrestotug Development After Disappointing Trial Results | GSK Stock News
GuruFocus News • 5:46am
GSK to Acquire Efimosfermin Alfa for Up to $2 Billion
GuruFocus News • 2:55am
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) | GSK Stock News
GuruFocus News • 1:30am
May 13, 2025
GSK Ends Collaboration on TIGIT Program Amid Lackluster Study Results | GSK Stock News
GuruFocus News • 1:15pm
GSK (GSK) and iTeos Halt Development of Lung Cancer Drug Combo
GuruFocus News • 7:59am
- 1
- 2
Show
Entries
Headlines
Total 0- 1
No recent news